Viking Therapeutics
VKTX
140 hedge funds and large institutions have $166M invested in Viking Therapeutics in 2021 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 38 increasing their positions, 37 reducing their positions, and 25 closing their positions.
235% more call options, than puts
Call options by funds: $3.13M | Put options by funds: $933K
28% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 25
4% more funds holding
Funds holding: 134 → 140 (+6)
3% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 37
2.03% less ownership
Funds ownership: 48.3% → 46.27% (-2%)
30% less capital invested
Capital invested by funds: $238M → $166M (-$71.4M)
Top Buyers
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.66M |
| 2 |
Renaissance Technologies
New York
|
+$1.36M |
| 3 |
Millennium Management
New York
|
+$821K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$779K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$591K |
Top Sellers
VKTX Hedge Fund Activity: Q4 2021 in Review
140 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q4 2021, worth a combined $166M — down 30% from $238M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new VKTX positions and 25 closed out — a net gain of 7 holders — while 38 added to existing stakes and 37 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $1.66M. The largest seller was Fiera Capital (Canada), cutting an estimated $5.7M.
- 140 institutional investors held Viking Therapeutics (VKTX) as of Q4 2021, up from 134 in Q3 2021.
- Funds reported $166M of Viking Therapeutics stock for Q4 2021, down 30% quarter-over-quarter.
- 32 funds opened new Viking Therapeutics positions in Q4 2021 and 25 closed out, a net change of +7 holders.
- The largest Viking Therapeutics buyer in Q4 2021 was Dimensional Fund Advisors, an estimated $1.66M added.
- The largest Viking Therapeutics seller in Q4 2021 was Fiera Capital (Canada), an estimated $5.7M sold.
Based on aggregated 13F filings for Q4 2021.